
doi: 10.1111/ane.12338
pmid: 25345888
To compare safety and efficacy of bridging approach with intravenous (IV) thrombolysis in patients with acute anterior strokes and proximal occlusions.Consecutive patients with ischemic anterior strokes admitted within a 4 h 30 min window in two different centers were included. The first center performed IV therapy (alteplase 0.6 mg/kg) during 30 min and, in absence of clinical improvement, mechanical thrombectomy with flow restoration using a Solitaire stent (StS); the second carried out IV thrombolysis (alteplase 0.9 mg/kg) alone. Only T, M1 or M2 occlusions present on CT angiography were considered. Endpoints were clinical outcome and mortality at 3 months.There were 63 patients in the bridging and 163 in the IV group. No significant differences regarding baseline characteristics were observed. At 3 months, 46% (n = 29) of the patients treated in the combined and 23% (n = 38) of those treated in the IV group had a modified Rankin scale (mRS) of 0-1 (P < 0.001). A statistical significant difference was observed for all sites of occlusion. In a logistic regression model, National Institute of Health Stroke Scale (NIHSS) and bridging therapy were independent predictors of good outcome (respectively, P = 0.001 and P = 0.0018). Symptomatic hemorrhage was documented in 6.3% vs 3.7% in the bridging and in the IV group, respectively (P = 0.32). There was no difference in mortality.Our results suggest that patients treated with a bridging approach were more likely to have minimal or no deficit at all at 3 months as compared to the IV treated group.
Male, 616.8, Mechanical Thrombolysis, Stroke/therapy, Thrombolytic Therapy/methods, Fibrinolytic Agents, 616, Humans, Thrombolytic Therapy, Fibrinolytic Agents/administration & dosage, Tissue Plasminogen Activator/administration & dosage, Aged, 616.0757, Mechanical Thrombolysis/methods, Middle Aged, Stroke, Tissue Plasminogen Activator, Administration, Administration, Intravenous, Female, Stents, Intravenous, ddc: ddc:616.0757, ddc: ddc:616, ddc: ddc:616.8
Male, 616.8, Mechanical Thrombolysis, Stroke/therapy, Thrombolytic Therapy/methods, Fibrinolytic Agents, 616, Humans, Thrombolytic Therapy, Fibrinolytic Agents/administration & dosage, Tissue Plasminogen Activator/administration & dosage, Aged, 616.0757, Mechanical Thrombolysis/methods, Middle Aged, Stroke, Tissue Plasminogen Activator, Administration, Administration, Intravenous, Female, Stents, Intravenous, ddc: ddc:616.0757, ddc: ddc:616, ddc: ddc:616.8
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 4 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
